Eagle Pharmaceuticals Inc... (EGRX)
0.65
null (null%)
At close: Jan 13, 2025, 8:00 PM
2.08
220.00%
Pre-market Oct 03, 2024, 10:10 AM EDT
undefined% (undefined)
| Bid | 2.27 |
| Market Cap | 8.42M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.85 |
| PE Ratio (ttm) | 0.76 |
| Forward PE | n/a |
| Analyst | Sell |
| Ask | 2.33 |
| Volume | 5,477 |
| Avg. Volume (20D) | 29,711 |
| Open | 1.00 |
| Previous Close | undefined |
| Day's Range | 0.65 - 1.00 |
| 52-Week Range | 0.00 - 6.81 |
| Beta | undefined |
About EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium ...
Sector Healthcare
IPO Date Feb 12, 2014
Employees 134
Stock Exchange NASDAQ
Ticker Symbol EGRX
Website https://www.eagleus.com
Analyst Forecast
According to 1 analyst ratings, the average rating for EGRX stock is "Sell." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 0.00%
Sell 100.00%
3 months ago ·
Source
-39.89%
Eagle Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
7 months ago ·
Source
-12.81%
Eagle Pharmaceuticals shares are trading lower after the company announced a Nasdaq listing receipt.
